PLK4 inhibition by CFI-400945 has been shown to have a synergistic anticancer effect with temozolomide in glioblastoma patient-derived xenograft mouse models [58]; etoposide or doxorubicin in medulloblastoma and rhabdoid tumors [84]; proteasome inhibitor bortezomib in multiple myeloma [79] and glioblastoma [59]; ATM inhibitor AZD0156 in uterine leiomyosarcoma [56]; and CDK2 (cyclin-dependent kinase 2) inhibitor seliciclib in lung cancer [25]. Here, PLK4 is linked to rhabdoid tumor.